Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion

Clinical Therapeutics

Volumn 22, Issue 1, 2000, Pages 66-75

  Burgess, David S ^a,b   Hastings, Rhonda W ^a,b   Hardin, Thomas C ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Beta lactams; Cefepime; Continuous infusion; Intermittent bolus infusion; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; ENTEROBACTER CLOACAE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS;

EID: 0033968045     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)87978-3     Document Type: Article

References (31)

1. 1. Craig WA, Ebert SC. Continuous infusion of β-lactam antimicrobials. Antimicrob Agents Chemother. 1992;36:2577-2583.
2. 2. Schentag JJ. Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics. Infect Med. 1992;9(Suppl B): 10-12.
3. 3. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89-96.
4. 4. Fluckinger U, Segessenmann C, Gerber AU. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother. 1991;35:1905-1910.
5. 5. Gengo FM, Mannion TW, Nightingale CH, Schentag JJ. Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. J Antimicrob Chemother. 1984;14:619-631.
6. 6. Leggett JE, Ebert S, Fantin B, Craig WA. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside, and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis. 1991;74:179-184.
7. 7. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989;159:281-292.
8. 8. Roosendaal R, Bakker-Woudenberg IA, Van den Berg JC, Michel MF. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis. 1985;152:373-378.
9. 9. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother. 1986;30:403-408.
10. 10. Chong Y, Lee K, Kwon OH. ln-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic Gram-negative bacilli. J Antimicrob Chemother. 1993;32(Suppl B):21-30.
11. 11. McGrath BJ, Bailey EM, Lamp KC, Rybak MJ. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1992;36:2741-2746.
12. 12. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med. 1979;67:608-616.
13. 13. Castela N, Taburet AM, Carlet J, et al. Pharmacokinetics of ceftazidime during continuous infusion in intensive care patients. Presented at 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Washington, DC.
14. 14. Daenen S, de Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet. 1988;i:1454. Letter
15. 15. Lagast H, Meunier-Carpentier F, Klastersky J. Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol Infect Dis. 1983;2:554-558.
16. 16. Lemmen S, Kropec A, Engels I, et al. Serum bactericidal activity after administration of four cephalosporins in healthy volunteers. Eur J Clin Microbiol Infect Dis. 1993;12:856-860.
17. 17. Mouton JW, Horrevorts AM, Mulder PGH, et al. Pharmacokineties of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother. 1990;34:2307-2311.
18. 18. Mouton JW, Michel MF. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother. 1991;28:911-918.
19. 19. Nicolau DP, Nightingale CH, Banevicius MA, et al. Serum bactericidal activity of ceftazidime: Continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996;40:61-64.
20. 20. Rio Y, Leroy F, Humbert G, Didion J. Comparative ceftazidime serum concentrations during continuous infusion in healthy subjects and severe burn patients. Presented at 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif.
21. 21. Zeisler JA, McCarthy JD, Richelieu WA, Nichol MB. Cefuroxime by continuous infusion: A new standard of care? Infect Med. 1992;11:54-60.
22. 22. Thornsberry C, Brown SD, Yee YC, et al. In-vitro activity of cefepime and other antimicrobials: Survey of European isolates. J Antimicrob Chemother. 1993;32(Suppl B):31-53.
23. 23. Barbahaiya RG, Forgue ST, Shyu WC, et al. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother. 1987; 31:55-59.
24. 24. Methods for Determining Bactericidal Activity of Antimicrobial Agents. Tentative Guidelines M26-T. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1992.
25. 25. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 4th ed. M7-A4. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1997.
26. 26. Methodology for the Serum Bactericidal Tests. Tentative Guidelines M21-T. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1992.
27. 27. Cappelletty DM, Kang SL, Palmer SM, Rybak MJ. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1995;39:1797-1801.
28. 28. Manduru M, Mihm LB, White RL, et al. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 1997;41:2053-2056.
29. 29. Benko AS, Cappelletty DM, Druse JA, Rybak MJ. Continuous infusion versus intermittent administration ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother. 1996;40:691-695.
30. 30. Nicolau DP, Lacy MK, McNabb JC, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Presented at 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif.
31. 31. Hanes SD, Wood GC, Croce MA, et al. Continuous vs intermittent infusion ceftazidime for the treatment of gram-negative nosocomial pneumonia. Pharmacotherapy. 1999;19:491. Abstract.